1. Home
  2. EQS vs CALC Comparison

EQS vs CALC Comparison

Compare EQS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equus Total Return Inc.

EQS

Equus Total Return Inc.

HOLD

Current Price

$1.01

Market Cap

16.2M

Sector

Finance

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.46

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQS
CALC
Founded
1991
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2M
19.1M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
EQS
CALC
Price
$1.01
$0.46
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
7.5K
353.4K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.46
52 Week High
$2.49
$7.20

Technical Indicators

Market Signals
Indicator
EQS
CALC
Relative Strength Index (RSI) 38.47 33.03
Support Level N/A N/A
Resistance Level $2.03 $0.73
Average True Range (ATR) 0.05 0.05
MACD -0.01 -0.01
Stochastic Oscillator 15.79 3.93

Price Performance

Historical Comparison
EQS
CALC

About EQS Equus Total Return Inc.

Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: